- Home
- / Pharmosa Biopharm
Pharmosa Biopharm
Stock Price
NT$61
2024-10-29
Market Capitalization
NT$7.8 B
2024-10-29
Revenue
NT$67.3 M
FY, 2025
Pharmosa Biopharm Summary
Company Summary
- Overview
- Pharmosa Biopharm (PBI) is a biotechnology company that focuses on developing drugs. Its products include inhalation formulations and drug-device combinations for pulmonary vascular, peripheral vascular, and other diseases.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- TW | view all locations
- Website
- https://www.pharmosa.com.tw/
- Cybersecurity rating
- Sectors
Table of Contents
LocationsView all
1 location detected
Taipei City HQ
Taiwan
3f, No. 3, Sanchong Rd, Nangang District
Pharmosa Biopharm Financials
Summary Financials
- Revenue (FY, 2025)
- NT$67.3M
- Gross profit (FY, 2025)
- NT$44.5M
- Net income (FY, 2025)
- (NT$383.8M)
- Cash (FY, 2025)
- NT$631.2M
- EBIT (FY, 2025)
- (NT$403.7M)
- Enterprise value
- $7.2B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026